Final analysis of the GRIFFIN study: Daratumumab with lenalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma
This Plain Language Summary of publication article (PLSP) from Future Oncology summarises the final analysis of the GRIFFIN study, which examines the effectiveness and safety of adding daratumumab (D) to a standard treatment regimen (RVd: lenalidomide, bortezomib, and dexamethasone) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplants. The study compared the outcomes of D-RVd plus D-R maintenance therapy versus RVd alone followed by R-only maintenance.
Visit the site using this link to read the article.
This PLSP is based on three articles called ‘Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial’ published in The Lancet Haematology, ‘Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN’ published in Blood Cancer Journal and ‘Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN’ published in the American Journal of Haematology.
Visit The Lancet using the link to read the original article.
Visit Nature using the link to read the original article.
Visit Wiley using the link to read the original article.